Top advances of the year: Melanoma
The United States Food and Drug Administration granted accelerated approval to lifileucel for adult patients who had unresectable or metastatic melanoma and were previously treated with an anti‑PD‑1 agent and targeted therapy if they were BRAF V600 mutation‑positive. (source sentence from article)
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Beyond the Five-Year Milestone: Long‑term Survivorship of Melanoma Patients Treated Off‑Trial with anti‑PD‑1
- Uveal Melanoma – Trials in Disease – Overview of Information and Clinical Research
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
- Melanoma Research
- The Clinical Trial Landscape for Melanoma Therapies